Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.

acute myeloid leukemia measurable residual disease molecular biology precision medicine surrogate biomarker

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
04 Feb 2023
Historique:
received: 30 12 2022
revised: 31 01 2023
accepted: 01 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

In acute myeloid leukemia (AML) many patients experience relapse, despite the achievement of morphological complete remission; therefore, conventional morphologic criteria are currently considered inadequate for assessing the quality of the response after treatment. Quantification of measurable residual disease (MRD) has been established as a strong prognostic marker in AML and patients that test MRD negative have lower relapse rates and better survival than those who test positive. Different techniques, varying in their sensitivity and applicability to patients, are available for the measurement of MRD and their use as a guide for selecting the most optimal post-remission therapy is an area of active investigation. Although still controversial, MRD prognostic value promises to support drug development serving as a surrogate biomarker, potentially useful for accelerating the regulatory approval of new agents. In this review, we will critically examine the methods used to detect MRD and its potential role as a study endpoint.

Identifiants

pubmed: 36834477
pii: ijms24043062
doi: 10.3390/ijms24043062
pmc: PMC9967250
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Cytometry B Clin Cytom. 2016 Jan;90(1):47-53
pubmed: 25906832
N Engl J Med. 2016 Feb 4;374(5):422-33
pubmed: 26789727
Curr Hematol Malig Rep. 2017 Dec;12(6):547-556
pubmed: 29027628
Front Oncol. 2019 Jul 23;9:655
pubmed: 31396481
JAMA Oncol. 2020 Dec 01;6(12):1890-1899
pubmed: 33030517
Leukemia. 2019 May;33(5):1102-1112
pubmed: 30542144
J Pers Med. 2020 Aug 20;10(3):
pubmed: 32825226
Br J Haematol. 2020 Jan;188(1):77-85
pubmed: 31804716
Blood. 2022 Apr 7;139(14):2145-2155
pubmed: 34995344
Cancer J. 2022 Jan-Feb 01;28(1):73-77
pubmed: 35072377
Blood. 2022 Sep 22;140(12):1345-1377
pubmed: 35797463
Cytometry B Clin Cytom. 2020 May;98(3):216-225
pubmed: 31697027
Haematologica. 2017 May;102(5):865-873
pubmed: 28126965
Haematologica. 2019 May;104(5):868-871
pubmed: 30923100
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
Blood. 2021 Dec 30;138(26):2753-2767
pubmed: 34724563
Haematologica. 2016 Mar;101(3):328-35
pubmed: 26635039
Blood. 2019 Apr 11;133(15):1630-1643
pubmed: 30803991
Blood. 2020 Dec 24;136(26):3041-3050
pubmed: 33367545
J Clin Oncol. 2016 Jul 20;34(21):2557-8
pubmed: 27185839
Blood. 2005 Dec 1;106(12):3733-9
pubmed: 16076867
Nat Rev Drug Discov. 2016 Jul;15(7):516
pubmed: 27256477
Front Oncol. 2021 Jan 15;10:603636
pubmed: 33575214
Blood. 2001 Jun 1;97(11):3574-80
pubmed: 11369653
Leukemia. 2010 Sep;24(9):1599-606
pubmed: 20668473
Leukemia. 2003 Dec;17(12):2318-57
pubmed: 14562125
Blood. 2018 Mar 22;131(12):1265-1266
pubmed: 29567752
Leukemia. 2016 Jul;30(7):1456-64
pubmed: 27012865
J Clin Oncol. 2010 Aug 10;28(23):3724-9
pubmed: 20625124
Blood. 2017 Mar 23;129(12):1627-1635
pubmed: 28159738
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Curr Protoc Cytom. 2020 Jun;93(1):e73
pubmed: 32311834
J Clin Oncol. 2022 Mar 10;40(8):855-865
pubmed: 34910556
Ann Oncol. 2016 Aug;27(8):1474-81
pubmed: 27084953
Genes Chromosomes Cancer. 2019 Dec;58(12):839-849
pubmed: 31478278
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Clin Oncol. 2016 Feb 1;34(4):329-36
pubmed: 26668349
Blood. 2019 Sep 19;134(12):935-945
pubmed: 31395600
J Clin Oncol. 2020 Apr 20;38(12):1273-1283
pubmed: 31860405
Biostatistics. 2000 Mar;1(1):49-67
pubmed: 12933525
Am J Hematol. 2019 May;94(5):528-538
pubmed: 30734356
PLoS One. 2014 Sep 22;9(9):e107587
pubmed: 25244440
Mayo Clin Proc. 2016 May 10;:
pubmed: 27236424
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221

Auteurs

Elisa Meddi (E)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Arianna Savi (A)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Federico Moretti (F)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Flavia Mallegni (F)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Raffaele Palmieri (R)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Giovangiacinto Paterno (G)

Hematology, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy.

Elisa Buzzatti (E)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Maria Ilaria Del Principe (MI)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Francesco Buccisano (F)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Adriano Venditti (A)

Hematology, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy.

Luca Maurillo (L)

Hematology, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH